Recent advances in the development of vaccines for chronic inflammatory autoimmune diseases
2018 (English)In: Vaccine, ISSN 0264-410X, E-ISSN 1873-2518, Vol. 36, no 23, p. 3208-3220Article in journal (Refereed) Published
Abstract [en]
Chronic inflammatory autoimmune diseases leading to target tissue destruction and disability are not only causing increase in patients' suffering but also contribute to huge economic burden for the society. General increase in life expectancy and high prevalence of these diseases both in elderly and younger population emphasize the importance of developing safe and effective vaccines. In this review, at first the possible mechanisms and risk factors associated with chronic inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus erythematosus (SLE) and type 1 diabetes (T1D) are discussed. Current advances in the development of vaccines for such autoimmune diseases, particularly those based on DNA, altered peptide ligands and peptide loaded MHC II complexes are discussed in detail. Finally, strategies for improving the efficacy of potential vaccines are explored. © 2018 Elsevier Ltd
Place, publisher, year, edition, pages
London: Elsevier, 2018. Vol. 36, no 23, p. 3208-3220
Keywords [en]
Chronic inflammatory autoimmune diseases, MS, RA, SLE, TID, Vaccines
National Category
Rheumatology and Autoimmunity
Identifiers
URN: urn:nbn:se:hh:diva-48389DOI: 10.1016/j.vaccine.2018.04.062ISI: 000435748500004PubMedID: 29706295Scopus ID: 2-s2.0-85046170088OAI: oai:DiVA.org:hh-48389DiVA, id: diva2:1703103
Note
Funding text: KSN would like to thank Southern Medical University, Guangzhou, PR China for startup grant (C1034211). We acknowledge team grant from Guangdong province (201001Y04675344) and matching grant from Dongguan city, PR China.
2022-10-122022-10-122022-10-20Bibliographically approved